CFI Pathogen Inactivation Technology
CFI病原体灭活技术
基本信息
- 批准号:7830669
- 负责人:
- 金额:$ 50万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-09-30 至 2011-08-31
- 项目状态:已结题
- 来源:
- 关键词:Acquired Immunodeficiency SyndromeAmericanAnimal VirusesAntibodiesApplications GrantsBabesiaBacteriaBiologicalBioterrorismBloodBlood donor screeningChemicalsClinical TrialsCollaborationsCommunity HealthcareConduct Clinical TrialsCyclic GMPDeforestationDepartment of DefenseDetergentsDevelopmentDiseaseDisease OutbreaksEnglandEnsureEnzyme ImmunoassayEnzymesEpidemicEscherichia coliEukaryotaEuropeEvaluationExcisionExhibitsFactor VIIIFibrinogenGasesGrantHIVHabitatsHeatingHumanHuman Parvovirus B19IndividualInfectionInfectious AgentInfluenzaInfluenza A Virus, H5N1 SubtypeInstitutesInternationalLaboratoriesLeadLiquid substanceLondonManufacturer NameMethodsMexicanModelingMorbidity - disease rateMutationNational Heart, Lung, and Blood InstituteOperative Surgical ProceduresParasitesPenetrationPharmacologic SubstancePharmacologyPhasePlasmaPlasma ProteinsPlasmodiumPoliomyelitisProcessProkaryotic CellsPropertyProteinsRecombinantsRecoveryRed CrossResearchResidual stateRiskRuptureSaccharomyces cerevisiaeSafetyScreening procedureSevere Acute Respiratory SyndromeSmall Business Innovation Research GrantSmallpoxSolventsStagingTechniquesTechnologyTestingTherapeutic Monoclonal AntibodiesThickTransfusionTransgenic OrganismsTravelUnited States National Institutes of HealthUrbanizationVaccinesVascular blood supplyVesicular stomatitis Indiana virusViralViral AntigensVirusVirus InactivationWest Nile virusWorkauthoritybaseclinical toxicologydesigndesign and constructionhealthy volunteerirradiationmeetingsmicroorganismmortalitypandemic diseaseparticlepasteurizationpathogenpathogenic bacteriapre-clinicalpreclinical studyprogramsprototypepublic health relevanceresearch and developmentresponseserological markerswine fluultraviolet irradiation
项目摘要
DESCRIPTION (provided by applicant): This project entitled "CFI Pathogen Inactivation Technology," is in response to the challenge of developing Enabling Technologies to "Ensure a safe and adequate blood supply through the development of new processing technologies" Topic 06-HL-106, p. 94 of the National Institutes of Health American Recovery and Reinvestment Act of 2009 Challenge Grant Omnibus Solicitation RFA-OD-09-003. The worldwide AIDS epidemic, the periodic emergence of Ebola and SARS, and the recent outbreaks of potentially pandemic strains of influenza such as H5N1 have highlighted a persistent concern in the healthcare community -- the need for effective pathogen inactivation and removal techniques for human blood plasma and plasma-derived products. There are also a number of emerging viruses such as West Nile and the breaking Mexican swine flu, and a number of potential bioterrorism pathogens such as smallpox that are of concern to the safety of the human plasma supply chain. In addition to viruses, bacteria and parasites such as Babesia spp. and Plasmodium spp. are major threats of spreading diseases through transfusion. The causes of the more rapid emergence and spread of these "killer" viruses and pathogens are not entirely known, but are thought to be caused by some combination of deforestation with urbanization of wild virus habitats, evolutionary mutations and rapid global travel. Annually, an estimated 3.8 million Americans are transfused with 28.2 million blood components derived from 12.8 million units of blood donated by apparently healthy volunteers. A rigorous scrutiny of blood donors and the screening of donated blood for various serological markers have significantly reduced the mortality and morbidity due to transfusion-associated infectious agents. Some enzyme immunoassays used for routine screening may detect viral antigens or antibodies, but not the infectious agents themselves. Thus, there could be an asymptomatic window period of infectivity responsible for a residual risk of post-transfusion infection. Current approaches such as pasteurization; solvent-detergent; UV irradiation; and chemical and photochemical inactivation not always effective against a wide spectrum of pathogens, are sometimes encumbered by process-specific deficiencies, and often result in denaturation of the biologics that they are designed to protect. We plan to develop a physical pathogen inactivation process for non-enveloped and enveloped viruses as well as pathogenic bacteria and parasites in human plasma and plasma protein products. The process utilizes supercritical and near-critical fluids (SuperFluids(tm) or SFS). SuperFluids(tm) are normally gases which, when compressed, exhibit enhanced solvation, penetration and expansion properties. These gases are used to permeate and inflate the virus and pathogen particles. The overfilled particles are then decompressed and, as a result of rapid phase conversion, rupture at their weakest points. Research to date indicates that the SuperFluids(tm) CFI (critical fluid inactivation) process inactivates both enveloped viruses such as MuLV, VSV, TGE, BDVD, Sindbis and HIV and nonenveloped viruses such as Polio, Adeno, Reo, Parvo and EMC while preserving biological activity of the treated product. In a research collaboration with the National Institute of Biological Standards and Control (NIBSC), London, England, we demonstrated that SuperFluids(tm) CFI can inactivate more than 4 logs of human Parvovirus B19 (one of the smallest and toughest viruses) in human plasma in a two-stage CFI unit in less than 20 seconds. We have also demonstrated that SFS can disrupt and inactivate microorganisms such as E. coli, and thick-walled prokaryotes such as B. subtilis and tough eukaryotes such as S. cerevisiae at viral inactivation SFS conditions. CFI can be used with conventional viral reduction methods such as SD and nanofiltration as an orthogonal method of pathogen clearance. Our specific plans for this challenge grant are to: (1) design and construct laboratory-scale prototypes to conduct evaluation and trade-off studies that will lead to the selection of a commercial-scale SFS-CFI design to achieve > 6 logs of inactivation levels of nonenveloped and enveloped viruses with >90% retention of protein (e.g., Factor VIII) integrity; (2) test prototypical and emerging viruses and bacteria in human plasma in extant SFS-CFI units and in laboratory-scale prototypes in order to establish universal operation conditions as well as
the universality of the SFS-CFI process for enveloped and nonenveloped viruses and pathogenic bacteria; (3) evaluate the potential of applying SFS-CFI enabling technology to human plasma proteins such as fibrinogen and other components; and (4) evaluate compatibility of SFS-CFI with other enabling pathogen inactivation/ reduction technologies such as nanofiltration to define orthogonal effective approaches to meet manufacturers' specifications and FDA requirements. Subsequently, with a pharmaceutical/biologics partner such as Baxter International and/or an institutional partner such as the American Red Cross, DOD or NHLBI, we plan to conduct pre-clinical studies, file an IND with the FDA and conduct clinical trials on CFI-treated plasma. A generally-applicable physical technology for inactivating viruses and emerging pathogens with high retention of biological activity will help ensure a blood supply that is safe from emerging and unknown pathogens as well as bioterrorism threats. In addition to human plasma and human plasma proteins, the developed technology will also be applicable to recombinant therapeutics, monoclonal antibodies, transgenics and vaccines.
PUBLIC HEALTH RELEVANCE: There are a number of emerging viruses such as West Nile, Ebola, SARS, potential pandemic strains of influenza (H5N1), the breaking Mexican swine flu, bacteria, parasites and a number of potential bioterrorism pathogens such as smallpox that are of concern to the safety of the human plasma supply. Current approaches are not always effective against a wide spectrum of human and animal viruses, are sometimes encumbered by process-specific deficiencies, and often result in denaturation of the biologicals that they are designed to protect. CFI pathogen inactivation technology gives pathogens the "bends," inactivating them without damaging proteins and enzymes in medically important transfusion fluids such as human plasma. This purely physical technique does not involve the use of heat, chemicals and/or irradiation, each of which has significant drawbacks in the viral inactivation of human plasma. As such, while CFI is capable of inactivating wide classes of viruses, bacteria and parasites, CFI has negligible negative impact on biological integrity and potency of the treated fluids. We plan to develop this technology as an orthogonal virus inactivation technology to techniques such as solvent-detergent (SD) that is not effective against non-enveloped viruses and passive virus removal techniques such as nanofiltration which does not render viruses inactive. This orthogonal approach is consistent with the regulatory authorities in Europe and the US that require a minimum of two pathogen inactivation technologies, which work by different mechanisms of action. The potential impact of a generally-applicable physical technology for inactivating viruses and emerging pathogens with high retention of biological activity will be very significant. Such a technology, especially when used with conventional virus inactivation or removal methods such as SD or nanofiltration, will help ensure a blood supply that is safe from emerging and unknown pathogens and bioterrorism threats. In addition to human plasma and human plasma proteins such as fibrinogen, the developed technology will also be applicable to recombinant therapeutics, monoclonal antibodies, transgenics and vaccines.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TREVOR P. CASTOR其他文献
TREVOR P. CASTOR的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TREVOR P. CASTOR', 18)}}的其他基金
Double-Encapsulated mRNA Vaccine for COVID-19
适用于 COVID-19 的双囊 mRNA 疫苗
- 批准号:
10611763 - 财政年份:2023
- 资助金额:
$ 50万 - 项目类别:
Combination Therapeutic for Chronic Opioid Use Disorder Relapse
慢性阿片类药物使用障碍复发的联合治疗
- 批准号:
10706844 - 财政年份:2023
- 资助金额:
$ 50万 - 项目类别:
Development of cGMP Manufacturing Process for CBD
CBD cGMP 生产工艺的开发
- 批准号:
8966448 - 财政年份:2015
- 资助金额:
$ 50万 - 项目类别:
Development of cGMP Manufacturing Process for CBD
CBD cGMP 生产工艺的开发
- 批准号:
8834719 - 财政年份:2014
- 资助金额:
$ 50万 - 项目类别:
相似国自然基金
美国敏感数据跨境传输禁令下浙江算力产业反制突围面临的障碍与突破路径研究
- 批准号:2025C25002
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
CAPA神经肽及其受体在美国白蛾越冬蛹中信号转导的分子机理研究
- 批准号:
- 批准年份:2024
- 资助金额:0.0 万元
- 项目类别:省市级项目
美国经济制裁对中国企业海外子公司战略响应的影响研究
- 批准号:
- 批准年份:2024
- 资助金额:万元
- 项目类别:青年科学基金项目
多算法集合模型下美国白蛾入侵风险及扩散机制研究
- 批准号:
- 批准年份:2024
- 资助金额:0.0 万元
- 项目类别:省市级项目
美国对华高科技企业出口管制:触发机制、创新影响与应对策略
- 批准号:72303146
- 批准年份:2023
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
中国ICT产业的供应链韧性测度与美国制裁风险的综合评估研究
- 批准号:2023JJ30172
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
美国推动供应链重塑对中国经济的影响及对策研究
- 批准号:72373076
- 批准年份:2023
- 资助金额:41 万元
- 项目类别:面上项目
制裁冲击与公司财务行为:基于美国对华管制清单的研究
- 批准号:72372172
- 批准年份:2023
- 资助金额:40.00 万元
- 项目类别:面上项目
AMPK信号调控美国白蛾海藻糖代谢与几丁质合成的分子机理
- 批准号:32371880
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
美国白蛾性信息素结合蛋白响应杀虫剂的分子机制
- 批准号:32371890
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
相似海外基金
Collaborative Research: REU Site: Earth and Planetary Science and Astrophysics REU at the American Museum of Natural History in Collaboration with the City University of New York
合作研究:REU 地点:地球与行星科学和天体物理学 REU 与纽约市立大学合作,位于美国自然历史博物馆
- 批准号:
2348998 - 财政年份:2025
- 资助金额:
$ 50万 - 项目类别:
Standard Grant
Collaborative Research: REU Site: Earth and Planetary Science and Astrophysics REU at the American Museum of Natural History in Collaboration with the City University of New York
合作研究:REU 地点:地球与行星科学和天体物理学 REU 与纽约市立大学合作,位于美国自然历史博物馆
- 批准号:
2348999 - 财政年份:2025
- 资助金额:
$ 50万 - 项目类别:
Standard Grant
Understanding Latin American Challenges in the 21st Century (LAC-EU)
了解拉丁美洲在 21 世纪面临的挑战 (LAC-EU)
- 批准号:
EP/Y034694/1 - 财政年份:2024
- 资助金额:
$ 50万 - 项目类别:
Research Grant
Conference: North American High Order Methods Con (NAHOMCon)
会议:北美高阶方法大会 (NAHOMCon)
- 批准号:
2333724 - 财政年份:2024
- 资助金额:
$ 50万 - 项目类别:
Standard Grant
Collaborative Research: RUI: Continental-Scale Study of Jura-Cretaceous Basins and Melanges along the Backbone of the North American Cordillera-A Test of Mesozoic Subduction Models
合作研究:RUI:北美科迪勒拉山脊沿线汝拉-白垩纪盆地和混杂岩的大陆尺度研究——中生代俯冲模型的检验
- 批准号:
2346565 - 财政年份:2024
- 资助金额:
$ 50万 - 项目类别:
Standard Grant
REU Site: Research Experiences for American Leadership of Industry with Zero Emissions by 2050 (REALIZE-2050)
REU 网站:2050 年美国零排放工业领先地位的研究经验 (REALIZE-2050)
- 批准号:
2349580 - 财政年份:2024
- 资助金额:
$ 50万 - 项目类别:
Standard Grant
Collaborative Research: RUI: Continental-Scale Study of Jura-Cretaceous Basins and Melanges along the Backbone of the North American Cordillera-A Test of Mesozoic Subduction Models
合作研究:RUI:北美科迪勒拉山脊沿线汝拉-白垩纪盆地和混杂岩的大陆尺度研究——中生代俯冲模型的检验
- 批准号:
2346564 - 财政年份:2024
- 资助金额:
$ 50万 - 项目类别:
Standard Grant
Conference: Latin American School of Algebraic Geometry
会议:拉丁美洲代数几何学院
- 批准号:
2401164 - 财政年份:2024
- 资助金额:
$ 50万 - 项目类别:
Standard Grant
Collaborative Research: Ionospheric Density Response to American Solar Eclipses Using Coordinated Radio Observations with Modeling Support
合作研究:利用协调射电观测和建模支持对美国日食的电离层密度响应
- 批准号:
2412294 - 财政年份:2024
- 资助金额:
$ 50万 - 项目类别:
Standard Grant
Conference: Doctoral Consortium at Student Research Workshop at the Annual Conference of the North American Chapter of the Association for Computational Linguistics (NAACL)
会议:计算语言学协会 (NAACL) 北美分会年会学生研究研讨会上的博士联盟
- 批准号:
2415059 - 财政年份:2024
- 资助金额:
$ 50万 - 项目类别:
Standard Grant